Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  EntreMed Inc    

SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Develops pharmaceutical drugs for treating cancer and inflammatory diseases

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs with commercial focus on the China market.

The Company operates through one business segment, which is the development of targeted therapeutics primarily for the treatment of cancer.

The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau.

The drugs are Captisol-Enabled, ZEVALIN and MARQIBO.

CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.
Managers
NameAgeSinceTitle
Ken Keyong Ren MD, PhD572012Chief Executive Officer & Director
Wei-Wu He PhD, MBA512012Executive Chairman
Cynthia Wong Hu462006COO, Secretary, Vice President & General Counsel
Sara B. Capitelli, CPA492011Chief Accounting Officer & Vice President-Finance
Rong Chen MD, PhD-2015Chief Medical Officer
Zuie Chin Huang, MBA502013Independent Director
Yue Alexander Wu PhD, MBA522013Independent Director
Franklin Cary Salisbury, Jr.602014Independent Director
Rajesh C. Shrotriya, MD722014Independent Director
Quan Zhou, PhD582016Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 49,537,267 22,830,087 46.1% 79,545 0.2% 46.1%
Shareholders
NameEquities%
He Xie Ai Qi Investment Management Beijing Co. Ltd. 8,498,765 20.0%
Spectrum Pharmaceuticals, Inc. 8,239,517 19.3%
IDG Capital Partners Co., Ltd. 6,842,783 16.1%
Zhejiang Kanglaite Group Co. Ltd. 2,057,613 4.83%
Wellington Shields Capital Management LLC 561,408 1.32%
Wellington Shields & Co. LLC 489,327 1.15%
Emerging Technology Partners LLC 441,072 1.04%
Kleiner Perkins Caufield & Byers LLC 416,666 0.98%
The Vanguard Group, Inc. 382,798 0.90%
Tak W. Mak, PhD 365,376 0.86%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Advertisement
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
ENTREMED INC57
INCYTE CORPORATION-24.41%15 412
CELLTRION, INC.--.--%11 588
LONZA GROUP AG14.04%10 300
QUINTILES TRANSNATIONA..11.55%9 074
ALKERMES PLC-42.87%6 873
SEATTLE GENETICS, INC.4.86%6 613
QIAGEN NV-0.54%6 592
ALNYLAM PHARMACEUTICAL..-19.08%6 531
UNITED THERAPEUTICS CO..-17.34%5 627
ICON PLC-1.61%4 240
ACADIA PHARMACEUTICALS..-3.73%4 110
IONIS PHARMACEUTICALS ..-45.31%4 096
BIO-TECHNE CORP19.10%3 989
CHARLES RIVER LABORATO..3.98%3 953
PAREXEL INTERNATIONAL ..2.20%3 682
INTREXON CORP-1.03%3 531
PRA HEALTH SCIENCES IN..14.31%3 153
BB BIOTECH AG-16.85%2 831
INC RESEARCH HOLDINGS ..-5.32%2 521
GALAPAGOS-15.84%2 497
Sector Biotechnology & Medical Research - NEC
EntreMed Inc : Connections
Cytomyx Holdings Plc
Human Longevity, Inc.
Emerging Technology Partners LLC
MithraGen, Inc.
Amnis Corp.
OriGene Technologies, Inc.
Wuhan Kindstar Diagnostics Co., Ltd.
IDG Technology Venture Investment, Inc.
Intradigm Corp.
IDG Technology Venture Investment IV LLC
Beijing Genetron Biotechnology Co. Ltd.
Crown Bioscience, Inc.
WUPIMA, Inc.
National Foundation for Cancer Research
Creditease Holdings Cayman Ltd.
Allos Therapeutics, Inc.
Superdata Technology (Asia) Ltd.
ImmunoVentis, Inc.
CVie Therapeutics Co. Ltd.
Zenesis Ltd.
IDG Capital Partners Co., Ltd.
Chiral Quest (Suzhou) Co. Ltd.
Circle Internet Financial, Inc.
OMNI Pharmaceuticals (USA), Inc.
American-Sino OB/GYN Hospital
Smooth Prosper Ltd.
IDG Technology Venture Investment III LLC
KPCB China Fund II LP
IDG Technology Venture Investments LP
Company contact information
CASI Pharmaceuticals, Inc.
9620 Medical Center Drive
Suite 300
Rockville, MD 20850

Phone : +1.240.864.2600
Fax : +1.240.315.2437
Web : www.casipharmaceuticals.com
© 2016 People , Fundamentals and Ownership